Zocilurtatug pelitecan

N/A

Report date: 2026/05/13 20:02:10
First In Class

Base Information

Drug NameZocilurtatug pelitecan
Drug Alias NamezociZL-1310YL-212
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)Biologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linker +[4
Mechanisms of ActionAnti-Delta-like protein 3DNA topoisomerase I inhibitors
TargetsDelta-like protein 3DNA topoisomerase I
Therapy Area/IndicationsSolid tumoursSmall Cell Lung Carcinoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSpainMainland China +[4
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesZai Lab (Shanghai) Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Inactive CompaniesN/A
Active IndicationsSolid tumoursSmall Cell Lung Carcinoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A